

West London Mental Health NHS Trust Performance in Initiating Q2 17/18

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Reasons for Delay	Comments
17/SS/0013	202663	XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects with Mild Dementia due to Alzheimer's Disease (AD)	No		14			No	15/03/2017	20/06/2017	25/04/2017	21/06/2017	04/07/2017	-	F - No patients seen	
17/LO/0380	218003	CREAD 2 - A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of crenezumab in patients with prodromal to mild Alzheimer's disease	No	-	-	-	-	Site Not Confirmed	05/12/2016	03/05/2017	18/05/2017	-	-	Site declined to participate	-	-
16/NE/0399	215044	A Long-Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Dementia with Lewy Bodies (DLB)	Yes	15/06/2017	12	36	48	Yes	17/02/2017	28/04/2017	16/02/2017	05/05/2017	10/05/2017	-	-	-
16/WS/0138	208282	A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (ACADIA)	Yes	01/08/2017	13	112	125	No	20/03/2017	29/03/2017	06/02/2017	07/04/2017	11/04/2017	-	G - No patients consented	Patients seen but failed screening
16/LO/0891	192592	A Feasibility Trial of UCL's Power Up: A Smartphone App to Support Young People to Make Shared Decisions in Therapy	Yes	17/02/2017	2	43	45	Yes	20/12/2016	03/01/2017	18/08/2016	10/01/2017	05/01/2017	-	-	-
17/WM/0146	220303	A Placebo-Controlled,	No	-	-	-	-	Within 70	01/05/2017	21/09/2017	04/10/2016	-	-	-	-	-

		Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer's Disease.					Days									
16/LO/1622	189449	Investigation of a New Satiety Inducing Diet for the Treatment of Obesity in the NHS	No	-	6	-	Within 70 Days	24/04/2017	27/07/2017	26/09/2016	02/08/2017	02/08/2017	-	-	-	

West London Mental Health NHS Trust Performance in Delivery Q2 17/18

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
13/LO/1758	136392	A Phase III, Randomized, PlaceboControlled, ParallelGroup, DoubleBlind Clinical Trial to Study the Efficacy and Safety of MK8931 (SCH 900931) in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD).	Number Agreed	10	10	Date Agreed	24/11/2016	4	24/11/2016	4	Recruitment Finished	Recruitment target not achieved
14/LO/1994	161812	A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)	Number Agreed	15	15	Date Agreed	01/10/2016	5	30/05/2017	9	Recruitment Finished	
16/NE/0191	202345	A Phase 2b, double-blind, randomized, placebo-controlled study of RVT-101 in subjects with dementia with Lewy bodies (DLB)	Number Agreed	1	7	Date Agreed	31/12/2016	0	14/04/2017	3	Withdrawn By Sponsor	